Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Cash from Financing Activities (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Cash from Financing Activities readings, the most recent being $61.1 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 555718.18% to $61.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $306.4 million through Mar 2026, up 19951.9% year-over-year, with the annual reading at $245.3 million for FY2025, 93.81% up from the prior year.
  • Cash from Financing Activities hit $61.1 million in Q1 2026 for Oric Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $134.3 million in Q2 2025 and bottomed at $1000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $34.0 million, with a median of $695500.0 recorded in 2024.
  • The largest annual shift saw Cash from Financing Activities plummeted 100.0% in 2022 before it skyrocketed 555718.18% in 2026.
  • Oric Pharmaceuticals' Cash from Financing Activities stood at $24.8 million in 2022, then plummeted by 98.17% to $453000.0 in 2023, then increased by 26.93% to $575000.0 in 2024, then soared by 160.87% to $1.5 million in 2025, then soared by 3976.0% to $61.1 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Cash from Financing Activities are $61.1 million (Q1 2026), $1.5 million (Q4 2025), and $109.5 million (Q3 2025).